CB vs REGN · P/E 14, rev $59.40B vs P/E 14, rev $14.34B
Chubb Ltd (CB) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CB currently screens at market cap $114.26B and trailing P/E 13.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CB and REGN stock pages for the full models.
Not investment advice.